A DNA sequence encoding the human IGFBP4 protein (P22692-1) (Asp 22-Glu 258) was expressed with tag free.
Accession
P22692-1
Protein construction
IGFBP4 (22-258)
Source
HEK293
Purity
>95% as determined by SDS-PAGE.
Endotoxin
Less than 1.0 EU per μg by the LAL method.
Formulation
Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, 5% Trehalose, 5% mannitol.
Species
Human
Background
Insulin-like growth factor-binding protein 4 is a protein that in humans is encoded by the IGFBP4 gene. This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein binds both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. IGFBP-4 is a unique protein and it consistently inhibits several cancer cells in vivo and in vitro. Its inhibitory action has been shown in vivo in prostate and colon. It is secreted by all colon cancer cells. The protein itself does not prevent the formation of cancer. However it may reduce the growth of cancer and act as an apoptotic factor. IGFBP4 has been shown to interact with Insulin-like growth factor 1 and 2.
Usage guide
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped with blue ice. Bulk packages of recombinant proteins are provided as frozen liquid which are shipped with dry ice.
Storage
Please avoid repeated freeze-thaw cycles. Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃ It is recommended that aliquot the reconstituted solution to minimize freeze-thaw cycles.